Xilio Therapeutics (XLO) Revenue (2024 - 2026)

Xilio Therapeutics (XLO) has 3 years of Revenue data on file, last reported at $12.6 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 331.67% year-over-year to $12.6 million; the trailing twelve-month figure through Mar 2026 stood at $53.5 million (up 476.71% YoY), and the FY2025 full-year result was $43.8 million, up 589.88% from the prior year.
• Revenue retreated to $12.6 million in Q1 2026, from $13.7 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $19.1 million in Q3 2025 to a low of $1.7 million in Q4 2024.
• A 3-year average of $7.8 million and a median of $5.5 million in 2025 frame the typical range for Revenue.
• Peak annual rise in Revenue reached 742.51% in 2025, while the deepest fall reached 242.98% in 2025.
• Tracing XLO's Revenue over 3 years: stood at $1.7 million in 2024, then jumped by 693.85% to $13.7 million in 2025, then slipped by 7.58% to $12.6 million in 2026.
• Business Quant data shows XLO's Revenue at $12.6 million in Q1 2026, $13.7 million in Q4 2025, and $19.1 million in Q3 2025.